Sanofi: positive data in dermatitis for children

(CercleFinance.com) - At the Revolutionizing Atopic Dermatitis conference, Sanofi has announced that phase III data for Dupixent (dupilumab) has showed a significant improvement in uncontrolled severe atopic dermatitis in children aged 6 to 11.


The data supports the safety and tolerance profile observed in trials in adults and teenagers suffering from atopic dermatitis, including the numerically lower rate of skin infections compared to placebo.

Sanofi and Regeneron announced the first results from this trial in August 2019. The extension of Dupixent's indications to children aged 6 to 11 is currently under priority review by the FDA, which is set to decide on 26 May 2020.


Copyright (c) 2020 CercleFinance.com. All rights reserved.